The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
It's also a weak, it's not SERM, so it's not a selective estrogen receptor modifier, but it's probably a weak, it's probably an ERM as well or a non-selective estrogen receptor modifier. And that should help with decreasing negative feedback inhibition of estradiol in various locations and also increasing testosterone.
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
But if you say you have hypoestrogenism, the most common complaint that comes with it is endometriosis, which is overgrowth of the lining of the uterus. And those people could potentially, I think, that's one area where we might see tongkat supplementation more and more, because not only does it decrease aromatase. Like we mentioned, testosterone in females is higher than estrogen in females. So a lot of females get estrogen from aromatization as well. Peripheral estrogen is sometimes what we call it, because it's not directly produced in the ovaries. But they could be good candidates for tongkat if that's the case.
Yeah, absolutely. So there's a lot of women that have hyperestrogenism and unlike adrenal fatigue or andropause, there's actually ICD 10 codes for hypoestrogenism.